On Jan 09, major Wall Street analysts update their ratings for $Jasper Therapeutics (JSPR.US)$, with price targets ranging from $40 to $80.
BMO Capital analyst Etzer Darout maintains with a buy rating, and maintains the target price at $63.
Oppenheimer analyst Jay Olson maintains with a buy rating, and maintains the target price at $80.
Stifel analyst Benjamin Burnett maintains with a buy rating, and maintains the target price at $80.
BTIG analyst Justin Zelin maintains with a buy rating, and adjusts the target price from $90 to $64.
RBC Capital analyst Gregory Renza maintains with a buy rating, and adjusts the target price from $68 to $48.
Furthermore, according to the comprehensive report, the opinions of $Jasper Therapeutics (JSPR.US)$'s main analysts recently are as follows:
The sharp decline in Jasper Therapeutics' stock following initial data from BEACON highlights the current market's low tolerance for uncertainties within biotech sectors. While the data could have been stronger, the response seems excessive given the positive efficacy signals at 240mg and preliminary safety profiles. Better understanding of briquilimab's advantages and risks at future doses could potentially recalibrate the stock's valuation. The assessment of briquilimab's role in treating chronic spontaneous urticaria is still developing.
Following the recent presentation of data from the Phase 1b/2a BEACON study in chronic spontaneous urticaria, it has been noted that briquilimab proves active and efficacious in treating the condition, demonstrating a favorable early safety profile. Despite these positive findings, the stock has significantly declined. This is attributed to perceptions that briquilimab's market differentiation compared to competing treatments like Celldex's barzolvolimab is less significant. Future potential updates that could impact the stock include additional BEACON study data and preliminary asthma treatment data expected later this year.
Here are the latest investment ratings and price targets for $Jasper Therapeutics (JSPR.US)$ from 7 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.